Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Opening Session Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement

Oct

03

Today In Oncology

FDA Approves First-Line Pirtobrutinib for CLL-SLL

Lung Cancer AI Model May Predict Pneumonitis Risk From Immunotherapy

FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality

Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence

Advertisement

© 2026 HSP News Service, L.L.C.